<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        34-367-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOCDURNA 25MCG ORAL LYOPHILISATE TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DESMOPRESSIN ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral lyophilisate
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Catalent UK Swindon Zydis Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Catalent UK Swindon Zydis Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Ferring GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01BA02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nocdurna contains desmopressin , an antidiuretic, which reduces urine production.<br />Nocdurna is used for the treatment of nocturia (frequent need to get up to urinate at night) due to nocturnal polyuria (overproduction of urine during&nbsp;night) in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- if you are allergic to desmopressin or any of the other ingredients of this medicine<br />- if you suer from polydipsia (excessive thirst and increased uid intake) or psychogenic polydipsia (psychologically caused increased thirst and increased<br />uid intake)<br />- if you have known or suspected cardiac insuciency (heart failure in which the heart is not able to pump enough blood throughout the body)<br />- if you have any disease requiring treatment with diuretics<br />- if you have moderately or severely reduced kidney function<br />- if you have or have had hyponatraemia (low sodium level in the blood)<br />- if you have SIADH (hormone secretion disorder)<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Nocdurna.<br />It is especially important that you talk to your doctor before taking Nocdurna if:<br />-you have severe bladder dysfunction and problems urinating&nbsp;you are 65 years or older since your doctor will have to monitor the level of sodium in your blood (see the section 3 &ldquo;How to take Nocdurna&rdquo; below)<br />-you have low levels of sodium in your blood<br />-you have a medical condition(s) causing uid and/or electrolyte imbalance<br />-you have a medical condition(s) that could be made worse by uid and/or electrolyte disturbance<br />-you get an acute intercurrent illness (such as systemic infection, fever, and stomach u) as it may be necessary for the doctor to interrupt/reassess the<br />treatment with Nocdurna<br />-you have cystic brosis, coronary heart disease, high blood pressure, chronic kidney disease or pre-eclampsia<br />You must limit uid intake to a minimum from 1 hour before taking Nocdurna until 8 hours after taking Nocdurna. Treatment without simultaneous<br />reduction of uid intake may lead to water retention and/or mineral imbalances with or without accompanying warning signs and symptoms hereunder<br />such as headache, nausea/vomiting, weight gain and in severe cases, convulsions.<br />Other medicines and Nocdurna<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />It is especially important you tell it to your doctor if you are taking:<br />- tricyclic antidepressants, which are medicines used to treat e.g. depression (such as clomipramine, imipramine, desipramine)<br />- selective serotonine reuptake inhibitors (SSRIs), which are medicines used to treat e.g. depression or anxiety (such as citalopram, paroxetine, sertraline)<br />- chlorpromazine, which is an anti-psychotic medicinal product used to treat e.g. schizophrenia<br />- diuretics (water tablets such as thiazides or other types of diuretics)<br />- carbamazepine, which is used to treat e.g. bipolar disorder and epilepsy<br />- antidiabetic medicinal products used for type II diabetes (medicines in the sulfonylurea group), particularly chlorpropamide<br />- non-steroidal anti-inammatory drugs (NSAIDs), which are medicinal products used for the treatment of pain and inammation (e.g. aspirin and ibuprofen)<br />- oxytocin, which is a medicinal product used around childbirth<br />- lithium, which is used to treat e.g. bipolar disorder<br />- Loperamide, which is a medicinal product used for the treatment of diarrhoea<br />Nocdurna with food and drink : Nocdurna should not be taken with food, since the eect may be reduced.<br />Pregnancy, breast-feeding and fertility : If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your&nbsp;doctor or pharmacist for advice before taking this medicine. Your doctor will decide if you can use this medicine during pregnancy or if you are&nbsp;breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor&nbsp;or pharmacist if you are not sure.<br />The recommended dose is<br />-Women: 25 microgram daily, one hour before bedtime, administered under the tongue without water.<br />-Men: 50 microgram daily, one hour before bedtime, administered under the tongue without water.<br />Nocdurna is placed under the tongue where it dissolves without the need for water.<br />Instructions for use<br />1. Completely remove the end tab of a blister strip by tearing along the perforations, starting from the corner with the hand symbol.<br />2. Now remove one blister from the strip by tearing along the perforations.<br />3. Remove the foil on each blister, starting at the corner with the printed arrow, by peeling o the foil in the direction of the arrow. Do not push the<br />tablet through the foil.<br />4. Carefully take a tablet out of its blister. Place the tablet under the tongue and allow it to dissolve. Do not chew or swallow the tablet.<br />5. If a tablet breaks into more than two pieces while you are taking it out of its blister, do not take the broken pieces. Take a tablet from another blister.&nbsp;</p><p>You must limit uid intake to a minimum from 1 hour before taking Nocdurna until 8 hours after taking Nocdurna. If you experience any of the<br />following symptoms the treatment should be stopped and your doctor contacted: headache, nausea/vomiting, weight gain and, in severe cases,<br />convulsions (see the section &ldquo;Warnings and precautions&rdquo; above). Your doctor can choose to restart treatment. When restarting treatment, you must<br />strictly restrict uid intake. In addition, your doctor will closely monitor the sodium levels in your blood.<br />Use in elderly patients (65 years of age and older): If you are 65 years or older your doctor will have to monitor the level of sodium in your blood<br />before starting the treatment, during the rst week of treatment (4-8 days after initiation of the treatment) and again in about one month after the<br />initiation of the treatment.<br />Kidney impairment: If you have moderately or severely reduced kidney function, do not take Nocdurna Talk to your doctor.<br />Liver impairment: If you have impaired liver function you should talk to your doctor before taking Nocdurna.<br />Use in children and adolescents: This medicine is for use in adults only<br />If you take more Nocdurna than you should: It is important that you do not take more than the prescribed dose in any 24 hour period. Special<br />attention should be given to signs of hyperhydration of the body (water intoxication), such as. weight gain, headache, nausea and, in severe cases,<br />convulsions. Please consult your doctor if you have taken more Nocdurna than you should.<br />If you forget to take Nocdurna Do not take a double dose to make up for a forgotten tablet. Continue taking the tablets as usual on the next day.<br />If you stop taking Nocdurna Treatment should only be interrupted or stopped on advice of your doctor.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side eects, although not everybody gets them. Drinking too much uid may lead to a build up of water<br />which dilutes the salt in the body in severe cases. This can become a serious problem and may lead to convulsions.<br />Stop taking this medicine and tell your doctor immediately or go to your nearest casualty department if you experience one or more of these<br />symptoms:<br />- an unusually bad or prolonged headache<br />- confusion,<br />- unexplained weight gain<br />- nausea or vomiting.<br />Side Eects include:<br />Very common: may aect more than 1 in 10 people : Dry mouth.<br />Common: may aect up to 1in 10 people: Nausea, feeling unwell, muscle weakness and confusion due to decreased level of sodium in the blood<br />(hyponatraemia), Headache, Dizziness, Nausea , Diarrhoea.<br />Uncommon: may aect up to 1 to 100 people: Constipation, Stomach discomfort, Weakness (fatigue), Swelling of the tissue in the lower limbs<br />(peripheral oedema).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>5. How to store Nocdurna<br />Keep this medicine out of the sight and reach of children. Store Below 30&deg;C. Store in the original package in order to protect from moisture and light.<br />Use immediately upon opening individual tablet blister. Do not use this medicine after the expiry date which is stated on the carton and blister after<br />EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist<br />how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Nocdurna contains<br />-The active substance is desmopressin added as desmopressin acetate.<br />Each oral lyophilisate contains 25 microgram desmopressin. Each oral lyophilisate contains 50 microgram desmopressin.<br />-The other ingredients are 12.50 mg gelatin, 10.25 mg mannitol (E 421) and q.s. to pH 4.6-5.0 citric acid, anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nocdurna 25 microgram: White, round, oral lyophilisate tablet of approximately 12 mm marked
with 25 on one side.
Nocdurna 50 microgram: White, round, oral lyophilisate tablet of approximately 12 mm marked
with 50 on one side.
Laminated aluminium blister sheets in an outer carton. Each perforated unit dose blister
sheet contains 10 oral lyophilisates. Pack size: 10x1, 30x1, 90x1 or 100x1 oral lyophilisates.
Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Catalent UK Swindon Zydis Ltd, Frankland Road, Blagrove, Swindon,<br />Wiltshire SN5 8RU, United Kingdom<br />Marketing Authorisation Holder: Ferring GmbH, Wittland 11, D-24109 Kiel, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي نوكدورنا على الديسموبريسين وهو عبارة عن مضاد لإدرار البول الذي يعمل على خفض إنتاج البول.<br />يستعمل نوكدورنا لعلاج البوال الليلي (الحاجة المتكررة للتبول ليلا) الناتج عن افراز كمية من البول تزيد عن طاقة استيعاب المثانة (إنتاج مفرط للبول في الليل) عند البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول نوكدورنا<br />&bull; إن كنت تعاني من حساس ّ ية من الديسموبريسين، أو أحد مكونات هذا الدواء.<br />&bull; إن كنت تعاني من ال ُ عطاش (عطش شديد وتناول مفرط للسوائل) أو ُ عطاش نفسي المنشأ (عطش نفسي وتناول مفرط للماء).<br />&bull; إن كنت تعاني من قصور في القلب أو تشتبه في ذلك (قصور القلب حيث يكون القلب غير قادر على ضخ ما يكفي من الدم إلى جميع أنحاء الجسم).<br />&bull; إن كنت تعاني من مرض يستدعي العلاج بالأدوية الموجهة لإدرار البول.<br />&bull; إن كنت تعاني من قصور كلوي من معتدل إلى حاد.<br />&bull; إن كنت عانيت او تعاني من نقص الصوديوم في الدم (انخفاض نسبة الصوديوم في الدم).<br />&bull; إن كنت تعاني من متلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول (اضطراب الإفراز الهرموني).<br />تحذيرات واحتياطات<br />استشير طبيبك أو الصيدلي قبل أخذ نوكدورنا. من المهم جدا ان تتحدث الى طبيبك قبل تناول نوكدورنا:<br />&bull; إن كنت تعاني من اختلال وظيفي حاد للمثانة ومشاكل في التبول.<br />&bull; إن كنت في سن 65 سنة فما فوق فعلى طبيبك مراقبة نسبة الصوديوم في الدم (أنظر الفقرة 3 أدناه &quot; كيف تستخدم نوكدورنا؟&quot;).<br />&bull; إن كنت تعاني من انخفاض مستويات الصوديوم في الدم.<br />&bull; إن كنت تعاني من اعتلال أو عدة اعتلالات مرضية تؤدي إلى اختلال السائل و/أو الكهارل.<br />&bull; إن كنت تعاني من اعتلال أو عدة اعتلالات مرضية قد تتفاقم نتيجة اختلال السوائل و/أو الكهارل.<br />&bull; إن كنت تعاني من داء واغل حاد (كالتهاب في الدم، الحمى والنزلة المعدية) لأنه قد يستدعي وقف العلاج من طرف طبيبك أو إعادة تقييم العلاج بنوكدورنا.<br />&bull; كنت تعاني من تليف كيسي أو مرض القلب التاجي، فرط ضغط الدم، مرض كلوي مزمن أو مقدمات الارتعاج.<br />يجب عليك الحد من تناول السوائل على الأقل ساعة قبل أخذ نوكدورنا وإلى غاية 8 ساعات بعد أخذ نوكدورنا. يمكن أن يؤدي العلاج دون التخفيض المتزامن مع تناول السوائل إلى<br />احتباس الماء و/أو إلى الاختلالات المعدنية المصاحبة لذلك، مع او بدون علامات وأعراض التحذير مثل صداع الرأس، الغثيان / التقيأ، زيادة الوزن وفي الحالات الخطيرة الاختلاجات.<br />أدوية أخرى ونوكدورنا : يجب إعلام طبيبك أو الصيدلاني إن كنت تستخدم أو استخدمت مؤ ّ خرا أو قد تستخدم أي أدوية أخرى.<br />من المهم جدا إبلاغ طبيبك إذا كنت تأخذ:<br />&bull; مضادات الاكتئاب ثلاثية الحلقات، وهي عبارة عن أدوية تستعمل مثلا لعلاج الاكتئاب (مثل كلوميبرامين، ايميبرامين، ديسيبرامين).<br />&bull; مثبطات الاسترداد الانتقائية لسيروتونين، وهي عبارة عن أدوية تستعمل مثلا لعلاج الاكتئاب والقلق (مثل سيتالوبرام، باروكستين، سرترالين).<br />&bull; الكلوربرومازين، وهو دواء مضاد للذهان يُتناول لمعالجة الفصام على سبيل المثال.<br />&bull; مدرات البول (أقراص مائية مثل الثيازيد أو مدر بولي آخر).<br />&bull; الكربامازيبين الذي يستعمل لعلاج اضطراب الثنائية القطبية أو الصرع على سبيل المثال.<br />&bull; الأدوية المضادة للسكري المستعملة للنوع الثاني من السكري (الأدوية من مجموعة السلفونيل يوريا) الكلوربروباميد على وجه الخصوص.<br />&bull; مضادات الالتهاب غير الإستيرودية وهي أدوية تستعمل لمعالجة الألم والالتهاب (مثلا الأسبيرين وإيبوبروفان).<br />&bull; الأوكسيتوسين وهو دواء يستعمل في الفترة القريبة من الولادة.<br />&bull; الليثيوم وهو يستعمل مثلا لعلاج الثنائية القطبية.<br />&bull; اللوبيراميد وهو دواء يستعمل لعلاج الإسهال.<br />تناول نوكدورنا مع الأغذية والمشروبات: لا يجب تناول نوكدورنا مع الأغذية، قد يؤدي ذلك من تقليل فعاليته.<br />الحمل، الرضاعة والخصوبة: إذا كنت حاملا أو ترضعين طفلك، او تعتقدين بأنك حامل، أو تخططين للحمل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />طبيبك سوف يقرر إذا كان باستطاعتك استخدام هذا الدواء إذا كنت حاملا او مرضعة.<br />القدرة على قيادة السيارات واستخدام الآلات: ليس لنوكدورنا أي تأثير على القدرة على قيادة السيارات أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الرجاء إتباع تعليمات ال ّ طبيب بكل عناية عند تناول نوكدورنا، الرجاء استشارة الطبيب أو الصيدلاني إذا كنت غير متأكد.<br />الجرعة الموصى بها:<br />النساء: 25 ميكروغرام يوميا، يتم أخذها تحت اللسان ساعة قبل النوم، دون الحاجة الى ماء.<br />الرجال: 50 ميكروغرام يوميا، يتم أخذها تحت اللسان ساعة قبل النوم دون الحاجة الى ماء. يوضع نوكدورنا تحت اللسان حيث يذوب دون الحاجة لشرب الماء</p><p>طريقة الاستخدام<br />1. اسحب كليا طرف شريط الصفيحة بتمزيق الثقوب انطلاقا من الزاوية التي تشير الى علامة اليد.<br />2. ارفع الصفيحة من الشريط بتمزيق الثقوب.<br />3. ارفع الورقة من كل صفيحة انطلاقا من زاوية السهم المطبوع، بتمزيق الورقة في اتجاه السهم. لا تدفع القرص عن طريق الغشاء.<br />4. أخرج بحذر القرص من صفيحته. ضع القرص تحت اللسان واتركه يذوب. لا تمضغ أو تبلع القرص.<br />5. إذا انكسر القرص إلى أكثر من جزأين أثناء إخراجها من صفيحتها، لا تأخذ الأجزاء المنكسرة، بل خذ قرص اخر من صفيحة أخرى.</p><p>يجب عليك أن تحد من شرب السوائل ساعة على الأقل قبل أخذ نوكدورنا و 8 ساعات بعد أخذ نوكدورنا، إذا شعرت بأحد الأعراض التالية أوقف العلاج واتصل بطبيبك:<br />صداع، غثيان/تقيأ، زيادة في الوزن وفي الحالات الخطيرة اختلاج (أنظر الفقرة &quot;تحذيرات واحتياطات&quot; أعلاه).<br />يمكن لطبيبك أن يقرر استئناف العلاج. أثناء استئناف العلاج يجب عليك التأكد من التخفيف من شرب السوائل، إلى جانب ذلك، يراقب طبيبك عن قرب نسبة الصوديوم في الدم.<br />الاستخدام لدى الأشخاص الذين يبلغ سنهم ( 65 سنة وما فوق)<br />4 أيام بعد بدء العلاج) وأيضا بعد شهر تقريباً من بدء العلاج. - إذا كان سنك 65 سنة أو ما يتجاوز ذلك، يجب على طبيبك مراقبة نسبة الصوديوم في الدم قبل بدء العلاج، خلال الأسبوع الأول من بدء العلاج ( 8<br />القصور الكلوي<br />إذا كنت تعاني من تدني وظيفة الكلى بنسبة حاد الى معتدل، لا تتناول نوكدورنا وأخبر طبيبك بذلك.<br />القصور الكبدي<br />إذا كنت تعاني من عجز في وظيفة الكبد أخبر طبيبك بذلك قبل تناول نوكدورنا.<br />الاستخدام لدى الأطفال والمراهقين<br />هذا الدواء مخصص للاستخدام عند البالغين فقط.<br />اذا أخذت نوكدورنا أكثر من اللازم:<br />من المهم عدم تجاوز الجرعة الموصوفة خلال ال 24 ساعة. يجب إعطاء اهتمام خاص لعلامات فرط سوائل الجسم (التسمم المائي) مثل اكتساب الوزن، صداع، غثيان وفي الحالات الخطيرة اختلاجات.<br />استشير طبيبك إذا تناولت نوكدورنا أكثر من اللازم.<br />اذا نسيت أخذ نوكدورنا :<br />لا تتناول ضعف الجرعة لتعويض القرص الذي نسيت تناوله، استمر في تناول الأقراص بالطريقة المعتادة حتى اليوم التالي.<br />إذا توقفت عن أخذ نوكدورنا:<br />لا يجب قطع العلاج أو إيقافه بدون إذن طبيبك.<br />إن كانت لديك استفسارات أخرى بخصوص استعمال هذا الدواء، استشير طبيبك أو الصيدلاني.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يتسبب نوكدورنا في تأثيرات غير مرغوب فيها، مع انها لا تصيب الجميع.<br />يمكن أن يؤدي شرب الكثير من السوائل إلى تراكم الماء الذي يقلل من الملح في الجسم في الحالات الخطيرة.<br />قد يشكل هذا خطر ومن المحتمل أن يسبب اختلاجات.<br />توقف عن تناول هذا الدواء وأخبر طبيبك بذلك فورا أو اتجه إلى الطوارئ الأقرب إليك إذا شعرتم بأحد أو عدد من هذه الأعراض:<br />- صداع شديد أو مستمر على غير المعتاد<br />- ارتباك<br />- اكتساب غير مبرر للوزن<br />- غثيان وتقيأ<br />تشمل الأعراض الجانبية:<br />شائعة جداً: (يمكن أن تصيب أكثر من شخص واحد من كل 10 أشخاص)<br />- فم جاف<br />شائعة: (يمكن أن تصيب شخص واحد من كل 10 أشخاص)<br />- غثيان، شعور بوعكة، ضعف عضلي وارتباك بسبب نقص نسبة الصوديوم في الدم (نقص نتروجين الدم)<br />- صداع<br />- دوخة<br />- غثيان<br />- إسهال<br />غير شائعة: (يمكن أن تصيب شخص واحد من كل 100 أشخاص)<br />- إمساك<br />- آلام المعدة<br />- ضعف (تعب)<br />- انتفاخ أنسجة الأعضاء الداخلية (وذمة محيطية)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />يحفظ بعيدا عن متناول ونظر الأطفال.<br />يحفظ في درجة حرارة تحت 30 درجة مئوية.<br />يحفظ في العلبة الخارجية الأصلية، لحمايته من الرطوبة والإضاءة.<br />يستعمل فورا بعد فتح الصفيحة الفردية.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدون على العلبة الخارجية والصفيحة. يوافق تاريخ انتهاء الصلاحية آخر يوم من ذلك الشهر.<br />لا يجب التخلص من الأدوية عن طريق مياه الصرف الصحي أو مع النفايات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الأدوية الغير مستعملة، فهذه التدابير تساهم في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي الديسموبريسين المضافة على شكل أسيتات الديسموبريسين.<br />- يحتوي نوكدورنا 25 ميكروغرام: كل قرص سريع الذوبان على 25 ميكروغرام من الديسموبريسين.<br />- يحتوي نوكدورنا 50 ميكروغرام: كل قرص سريع الذوبان على 50 ميكروغرام من الديسموبريسين.</p><p>المكونات الأخرى هي 12.50 مغ جيلاتين، 10.25 مغ مانيتول&nbsp;( 421 E )&nbsp;وحمض السيتريك اللامائي (كمية كافية لتصل درجة الحموضة الى ( 4.6.(5.0</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني لنوكدورنا ومحتوى العلبة؟<br />نوكدورنا 25 ميكروغرام: قرص أبيض اللون، دائري، قرص سريع الذوبان حوالي 12 مم عليه علامة 25 على جانب واحد من القرص.<br />نوكدورنا 50 ميكروغرام: قرص أبيض اللون، دائري، قرص سريع الذوبان حوالي 12 مم عليه علامة 50 على جانب واحد من القرص.<br />أشرطة من الألمنيوم المصفح في علبة خارجية. يحتوي كل شريط مثقب للجرعة الواحدة على 10 اقراص سريعة الذوبان.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المصنع: كاتالينت سويندون زيدس المحدودة، فرانكلان رود بلاجروف&nbsp;SN5 8RU&nbsp;سويندون،</p><p>ويلتشاير، بريطانيا</p><p>حامل رخصة التسويق: فيرينغ جي آم بي آش، ويتلند 11&nbsp;-24109 D&nbsp; &nbsp;كييل، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أيلول 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nocdurna 25 microgram oral lyophilisate
Nocdurna 50 microgram oral lyophilisate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each oral lyophilisate contains desmopressin acetate equivalent to 25 or 50 microgram desmopressin.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral lyophilisate.
Nocdurna 25 microgram:
White, round, oral lyophilisate of approximately 12 mm marked with 25 on one side.
Nocdurna 50 microgram:
White, round, oral lyophilisate of approximately 12 mm marked with 50 on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nocdurna is indicated for symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults<br />(see section 5.1).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br /> Women: 25 microgram daily, one hour before bedtime, administered sublingually without water.<br /> Men: 50 microgram daily, one hour before bedtime, administered sublingually without water.<br />A dose increase with this product is not recommended in elderly patients &ge; 65 years.<br />If higher doses are considered for patients under the age of 65 years in case of an insufficient response to<br />Nocdurna, other desmopressin oral lyophilisate products should be used (see sections 4.4, 4.8 and 5.1)<br />In the event of signs or symptoms of water retention and/or hyponatremia (headache, nausea/vomiting,<br />weight gain, and, in severe cases, convulsions) treatment should be interrupted and reassessed. When<br />restarting treatment strict fluid restriction should be enforced and serum sodium levels monitored (see<br />section 4.4).<br />Nocdurna should be discontinued if the serum sodium level falls below the lower limit of normal range&nbsp;(i.e.135 mmol/L)</p><p>Special Populations<br />Elderly patients (65 years of age and older)<br />Elderly patients are at increased risk of developing hyponatraemia with desmopressin treatment and may<br />also have impaired renal function. Caution should therefore be exercised in this age group and daily doses<br />above 25 microgram for females and 50 microgram for males should not be used. In elderly patients serum<br />sodium must be within the normal range, before initiating treatment, in the first week (4-8 days after<br />initiation) and again at one month. Nocdurna should be discontinued if the serum sodium level falls below<br />the lower limit of normal range (see section 4.4). Continued therapy must be carefully reconsidered in<br />elderly patients who show no evidence of therapeutic benefit beyond 3 months.<br />Renal impairment<br />Nocdurna is contraindicated in patients with moderate and severe renal insufficiency (see section 4.3).<br />Hepatic impairment<br />No dose adjustment is needed for patients with hepatic impairment (see section 5.2).<br />Paediatric population<br />There is no relevant use of Nocdurna in the paediatric population for the indication of symptomatic<br />treatment of nocturia due to idiopathic nocturnal polyuria.<br />Method of administration<br />Nocdurna is placed under the tongue where it dissolves without the need for water.<br />Food intake may reduce the intensity and duration of the antidiuretic effect at low doses of desmopressin<br />(see section 5.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
 Habitual or psychogenic polydipsia (resulting in a urine production exceeding 40 ml/kg/24 hours)
 Known or suspected cardiac insufficiency or other conditions associated with fluid overload, sufficient to
require treatment with diuretics, including a history of such conditions
 Moderate and severe renal insufficiency (creatinine clearance below 50 ml/min)
 Known history of hyponatremia
 Syndrome of inappropriate ADH secretion (SIADH)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients, in particular the elderly, should undergo clinical examination and questioning before commencing<br />treatment with Nocdurna, given that nocturnal polyuria can be a symptom of cardiovascular or other medical<br />conditions associated with fluid overload. If there is any suspicion of such coexistent conditions, treatment<br />with desmopressin is not recommended (see also section 4.3).<br />Fluid intake must be limited to a minimum from 1 hour before until 8 hours after administration. Treatment<br />without concomitant reduction of fluid intake may lead to prolonged fluid retention and/or hyponatremia<br />with or without accompanying warning signs and symptoms (headache, nausea/vomiting, weight gain, and,<br />in severe cases, convulsions).<br />Elderly patients with serum sodium levels in the lower range of normal may have an increased risk of<br />hyponatremia. Patients 65 years and older should have their serum sodium monitored before initiating the&nbsp;treatment, in the first week of treatment (4-8 days) and again at one month after treatment initiation (see<br />section 4.2).<br />At a 50 microgram dose level females may have an increased risk of hyponatraemia compared with males<br />(see Section 5.1). It is therefore important that the gender-specific recommendations for dose are adhered to.<br />Nocdurna should be discontinued if the serum sodium level falls below the lower limit of normal range.<br />Desmopressin should be used with caution in patients with conditions characterized by fluid and/or<br />electrolyte imbalance.<br />Treatment with desmopressin should be interrupted and reassessed during acute intercurrent illnesses<br />characterised by fluid and/or electrolyte imbalance (such as systemic infections, fever, and gastroenteritis).<br />Precautions to avoid hyponatremia including careful attention to fluid restriction and more frequent<br />monitoring of serum sodium must be taken in case of concomitant treatment with drugs, which are known to<br />induce SIADH, e.g. tricyclic antidepressants, selective serotonin reuptake inhibitors, chlorpromazine,<br />diuretics and carbamazepine, and some antidiabetics of the sulfonylurea group, particularly chlorpropamide,<br />and in case of concomitant treatment with non-steroidal anti-inflammatory drugs (NSAIDs).<br />Special caution should be exercised in patients taking thiazide or loop diuretics for hypertension or other<br />medical conditions not associated with fluid overload. Sodium monitoring in these patients is warranted.<br />Severe bladder dysfunction and outlet obstruction should be considered before starting treatment.&nbsp;</p><p>Caution is required in cases of cystic fibrosis, coronary heart disease, hypertensions, chronic renal disease<br />and pre-eclampsia.<br />A diagnosis of nephrogenic diabetes insipidus should be considered if there is no reduction in night-time<br />urine output after commencement of desmopressin.<br />Special caution should be exercised in patients taking lithium in case of masking of early-stage lithiuminduced<br />nephrogenic diabetes insipidus by administration of desmopressin for a nocturia indication.<br />Desmopressin is not recommended in patients suspected of having lithium-induced nephrogenic diabetes&nbsp;insipidus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions<br />Substances, which are known to induce SIADH, may cause an increased risk of water<br />retention/hyponatremia (e.g. tricyclic antidepressants, selective serotonin reuptake inhibitors,<br />chlorpromazine, diuretics and carbamazepine as well as some antidiabetics of the sulfonylurea group<br />particularly chlorpropamide) (see section 4.4).<br />NSAIDs and oxytocin may potentiate the antidiuretic effect of desmopressin and may induce water<br />retention/ hyponatremia (see section 4.4).<br />Lithium may diminish the antidiuretic effect.<br />Pharmacokinetic interactions<br />Concomitant treatment with loperamide may result in a 3-fold increase of desmopressin plasma<br />concentrations following oral administration, which may lead to an increased risk of water&nbsp;retention/hyponatremia. Although not investigated, other drugs slowing intestinal transport might have the<br />same effect.<br />A standardised 27% fat meal significantly decreased absorption (rate and extent) of desmopressin tablets.<br />No significant effect was observed with respect to pharmacodynamics (urine production or osmolality).<br />Food intake may reduce the intensity and duration of the antidiuretic effect at low oral doses of&nbsp;desmopressin tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Caution should be exercised when prescribing to pregnant women.<br />Data on a limited number (n = 53) of exposed pregnancies in women with diabetes insipidus as well as data<br />on a limited number of exposed pregnancies in women with bleeding complications (n=216) indicate no<br />adverse effects of desmopressin on pregnancy or on the health of the foetus/newborn child. To date, no other<br />relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects<br />with respect to pregnancy, embryonic/foetal development, parturition or postnatal development.<br />Animal reproduction studies have shown no clinically relevant effects on parents and offspring. In-vitro<br />analysis of human cotyledon models have shown that there is no transplacental transport of desmopressin<br />when administered at therapeutic concentration corresponding to recommended dose.<br />Breastfeeding<br />Results from analyses of milk from nursing mothers receiving high dose desmopressin acetate (300<br />microgram intranasal); indicate that the amounts of desmopressin that may be transferred to the child are<br />considerably less than the amounts required to influence diuresis. Therefore it is not considered necessary to<br />stop breastfeeding.<br />Fertility<br />Studies with desmopressin in animals have shown no impairment of fertility in male and female rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nocdurna has no or negligible influence on the ability to drive and use machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Based on the frequency of adverse drug reactions reported in clinical studies with Nocdurna for nocturia<br />indication conducted in male subjects (50 mcg; N=222) and in female subjects (25 mcg; N=219) the most<br />commonly reported adverse reaction during treatment was dry mouth (13%), headache (3%), hyponatraemia<br />(3%), and dizziness (2%).<br />Description of selected adverse reactions:<br />The most serious adverse reaction with desmopressin is hyponatraemia, which is associated with headache,<br />nausea, vomiting, decreased serum sodium, weight increase, malaise, abdominal pain, muscle cramps,<br />dizziness, confusion, decreased consciousness and in severe cases convulsions and coma. The<br />hyponatraemia is an antidiuretic effect, arising from increased water re-absorption by the renal tubules and<br />osmotic dilution of plasma. In studies with adult subjects treated for nocturia, the majority of the subjects<br />developed low serum sodium within the first days of treatment or in relation to dose increase. Special<br />attention should be paid to the precautions addressed in section 4.4.</p><p>Females have a higher risk of hyponatraemia which may be due to increased sensitivity of the kidney tubules<br />to vasopressin and its analogues in women compared with men. The risk of this is minimised by<br />recommendation of a lower dose in women. The risk of hyponatraemia in the over 65 years age group is<br />further reduced by monitoring of serum sodium in this age group (see section 4.2 and 4.4).<br />Tabulated list of adverse reactions<br />The below table 1 shows the frequencies of adverse reactions reported. The frequencies are defined as<br />follows: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10) and uncommon (&ge;1/1,000 to &lt;1/100).<br />Table 1: Frequency of adverse drug reactions reported (Phase III studies and Post-marketing reports)&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>*It is to be noted that subjects were specifically queried about dry mouth in some of the clinical studies.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows<br />continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are<br />asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms:<br />Overdose of Nocdurna leads to a prolonged duration of action with an increased risk of water retention and<br />hyponatremia.<br />Treatment:<br />Although the treatment of hyponatraemia should be individualised, the following general recommendations<br />can be given. Hyponatraemia is treated by discontinuing the desmopressin treatment, fluid restriction and&nbsp;symptomatic treatment if needed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Vasopressin and analogues.<br />ATC code: H01B A02<br />Mechanism of action<br />Nocdurna contains desmopressin a synthetic analogue of naturally occurring anti-diuretic hormone arginine<br />vasopressin (AVP). Desmopressin mimics vasopressin&rsquo;s anti-diuretic effect, binding to the V2 receptors in<br />the renal collecting tubules of the kidneys, causing reabsorption of water into the body. This reabsorption in<br />turn decreases night-time urine production. Due to the proposed low gender-specific doses (25 microgram<br />for females and 50 microgram for males), and the limited duration of action ofNocdurna, the antidiuretic<br />activity is limited to the night-time sleep period.<br />Pharmacodynamic effects<br />In study CS29, the weight-corrected Nocdurna dose that induced 50% maximum achievable drug effect on<br />nocturnal urine volume differed significantly between females and males. The estimated exposure value for<br />males was 2.7-fold (95% CI: 1.3-8.1) higher than the value for females to obtain an identical dynamic effect,<br />corresponding to higher desmopressin sensitivity among females. The development of hyponatremia is dose<br />dependent. Females are at higher risk of developing hyponatraemia than males. The incidences of<br />hyponatremia rises with increasing age (see section 4.2 and 4.4).<br />Clinical efficacy<br />The efficacy of Nocdurna has been demonstrated in two randomised double blinded placebo controlled<br />studies in respectively 268 women (study CS40, desmopressin Melt 25 microgram versus placebo) and 395<br />men (study CS41, desmopressin Melt 50 microgram and 75 microgram versus placebo ) with nocturia<br />defined as an average of &ge;2 nocturnal voids per night and polyuria in 90% of women and 87% of men.<br />Both studies met the 2 co-primary endpoints with statistically significant differences favouring<br />desmopressin Melt over the 3-month period. There was a statistically significant decrease in the adjusted<br />mean number of nocturnal voids from the baseline on desmopressin Melt 25 microgram (-1.46) compared to<br />placebo (-1.24) in the female study (p=0.028) (Fig. 1) and on desmopressin Melt 50 microgram (-1.25)<br />compared to placebo (-0.88) in the male study (p=0.0003) (Fig. 2). The proportion of subjects with &gt;33%<br />decrease in the mean number of nocturnal voids (responders) was significantly increased, nearly doubled.<br />The odds ratio for &gt;33% decrease of desmopressin Melt 25 microgram compared to placebo was 1.85<br />(p=0.006) in the female study and the odds ratio for &gt;33% decrease of desmopressin Melt 50 microgram<br />compared to placebo was 1.98 (p=0.0009) in the male study.<br />For secondary endpoints, there was an increase from baseline to 3 months in the first undisturbed sleep<br />period (FUSP)/time to first void with a treatment contrast of 49 minutes in the female study and 39 minutes<br />in the male study. There was a statistically significant improvement in quality of life for desmopressin Melt<br />25 microgram (N-QoL total score 27.24) compared to placebo (21.90) (p=0.0226) in female and an<br />improvement for desmopressin Melt 50 microgram (N-QoL total score 18.37) compared to placebo (13.88)<br />(p=0.0385) in male. There was a strong association (p&lt;0.0001) in the both studies between treatment<br />response (reduction in number of nocturnal voids and increase in FUSP) and improvements in patients&rsquo;<br />quality of life.</p><p>&nbsp;</p><p>In a double-blind randomised clinical study, the efficacy and safety of a combination therapy with<br />desmopressin Melt and tolterodine extended release capsules was investigated for the treatment of<br />overactive bladder with nocturia in women, for a period of 3 months. Forty-nine subjects were exposed to a<br />combination of Nocdurna (desmopressin Melt) 25 microgram and tolterodine 4 milligram. No serious<br />adverse events were observed in this study and safety profile of the combination treatment was similar to the<br />safety profile of Nocdurna 25 microgram. The efficacy in terms of reduction from baseline in mean number<br />of nocturnal voids during 3 months treatment was numerically greater in the combination therapy group<br />versus tolterodine monotherapy group (treatment contrast, -0.34 voids) in full analysis set, and the difference<br />reached statistical significance (p=0.049) with a treatment contrast of -0.41 voids in the per protocol analysis<br />set.<br />Gender differences in clinical safety and efficacy<br />Clinical study [FE992026 CS029] analysed the dose-response to Nocdurna in females and males at doses<br />ranging from 10 to 100 microgram: In females, there was no further gain in pharmacodynamic effect above<br />the dose of 25 microgram, indicating that the dose response plateau was reached at 25 microgram in<br />females. In males, reduction in urine volume was greater at 50 microgram, but not substantially higher at<br />100 microgram. Increasing doses to 50 microgram dose level in females did not yield further efficacy, but<br />was associated with a 5-fold increase in the risk of hyponatraemia compared with males in the age group&nbsp;above 50 years (p = 0.015).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />The overall mean absolute bioavailability of desmopressin administered sublingually from earlier doseranging<br />studies of doses of 200, 400 and 800 mcg is 0.25%, with a 95% confidence interval of 0.21 &ndash;<br />0.31%. Desmopressin exhibits a moderate-to-high variability in bioavailability, both within and between<br />subjects. Desmopressin shows dose linearity regarding AUC and Cmax in the range of 60 to 240 mcg.<br />However, the bioavailability of doses below 60 has not been evaluated.<br />Distribution<br />The distribution of desmopressin is best described by a two-compartment distribution model with a volume<br />of distribution during the elimination phase of 0.3-0.5 L/kg.<br />Biotransformation<br />The in-vivo metabolism of desmopressin has not been studied. In vitro human liver microsome metabolism<br />studies of desmopressin have shown that no significant amount is metabolized in the liver by the cytochrome<br />P450 system. Thus human liver metabolism in vivo by the cytochrome P450 system is unlikely to occur. The<br />effect of desmopressin on the PK of other drugs is likely to be minimal due to its lack of inhibition of the<br />cytochrome P450 drug metabolizing system.<br />Elimination<br />The total clearance of desmopressin has been calculated to 7.6 L/hr. The terminal half-live of desmopressin<br />is estimated to 2.8 hours. In healthy subjects the fraction excreted unchanged was 52 % (44 % - 60 %).<br />Linearity/non-linearity<br />There are no indications of non-linearities in any of the pharmacokinetic parameters of desmopressin.</p><p>Characteristics in specific groups of patients<br />Renal impairment:<br />Depending on the degree of renal impairment the AUC and half-live increased with the severity of the renal<br />impairment. Desmopressin is contraindicated in patients with moderate and severe renal impairment<br />(creatinine clearance below 50 ml/min).<br />Table 2: Pharmacokinetic parameters for different degrees of renal impairment. Data from CS001.</p><p>Hepatic impairment:<br />No studies have been performed in this population.<br />It is unlikely that desmopressin will interact with drugs affecting hepatic metabolism, since desmopressin<br />has been shown not to undergo significant liver metabolism in in vitro studies with human microsomes.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction.<br />Carcinogenicity studies have not been performed with desmopressin, because it is closely related to the&nbsp;naturally-occurring peptide hormone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gelatin<br />Mannitol (E 421)<br />Citric acid, anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                N/A
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special temperature storage conditions.<br />Store in the original package in order to protect from moisture and light.<br />Use immediately upon opening individual tablet blister</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Perforated unit dose blisters packed in a carton. The blister bottom foil and the blister lid foil are multilayer<br />laminates consisting of PVC/OPA/Alu/OPA/PVC and heat seal laquer/Alu/PET/paper, respectively.<br />Pack size:<br />10x1, 30x1, 90x1 or 100x1 oral lyophilisates<br />Not all pack sizes may be marketed.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />Any unused medicinal product or waste material should be disposed in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ferring GmbH
Wittland 11,
24109 Kiel
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>